Literature DB >> 15682466

Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis.

I-Shyan Sheen1, Kuo-Shyang Jeng, Wen-Juei Jeng, Chi-Juei Jeng, Yi-Ching Wang, Shu-Ling Gu, Shin-Yun Tseng, Chien-Ming Chu, Chia-Hui Lin, Kuo-Ming Chang.   

Abstract

AIM: To investigate the effect and possible mechanisms of antiangiogenesis therapy for HCC in rats.
METHODS: Adult male LEW/SsN rats were divided into 3 groups, 25 animals each. Group A was the control group. Groups B and C were given diethylnitrosamine, 5 mg/kg/d. In addition, group C rats received an intraperitoneal injection of fumagillin, 30 mg/(kg x d). Five animals in each group were killed at 6th, 12th, 18th, 20th and 24th wk to evaluate the development of HCC and metastasis. Weight of the rats, liver tumors, and number of organs involved by HCC were measured at each stage. We compared methionine aminopeptidase-2 (MetAP-2) mRNA, Bcl-2 mRNA, telomerase mRNA, and telomerase activity at 24th wk in the liver tissue of group A rats and tumor tissue of HCC from group B and C rats.
RESULTS: No HCC developed in group A, but tumors were present in group B and C rats by the 18th wk. At wk 20 and 24, the median liver weight in group B was 0.64 g (range: 0.58-0.70 g) and 0.79 g (range: 0.70-0.90 g) (P = 0.04), and that in group C was 0.37 g (range: 0.35-0.42 g) and 0.39 g (range: 0.35-0.47 g) (P = 0.67). The liver weight in group C rats was significantly lower than that in group B rats (P = 0.009). At the same time, the median metastasis score (number of organ systems involved) was 3 (range2-3) in group B, and 1 (range 1-2) in group C, a significant difference between the groups (P = 0.007, 0.004). The levels of MetAP-2 mRNA were significantly higher in groups B and C than in group A (P = 0.025), and significantly higher in group C than in group B (P = 0.047). The level of Bcl-2 mRNA was significantly higher in group B than in group A (P = 0.024), but lower in group C than in group B, although not significantly (P = 0.072). Telomerase mRNA was significantly higher in group B than in group A (P = 0.025), but significantly lower in group C than in group B (P = 0.016). The same inter-group relationship was also true for telomerase activity (P = 0.025 and 0.046).
CONCLUSION: Fumagillin effectively inhibits both liver tumor growth and metastasis in rats in vivo. A possible mechanism is fumagillin-induced inhibition of MetAP-2, which plays an essential role in endothelial cell proliferation. Inhibition of MetAP-2 also results in inhibition of Bcl-2 and telomerase activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682466      PMCID: PMC4250582          DOI: 10.3748/wjg.v11.i6.771

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

Review 1.  Surgical implications of therapeutic angiogenesis.

Authors:  M A Zimmerman; C H Selzman; A H Harken
Journal:  Surgery       Date:  1999-03       Impact factor: 3.982

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

Authors:  N Sin; L Meng; M Q Wang; J J Wen; W G Bornmann; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC.

Authors:  K Kenmochi; S Sugihara; M Kojiro
Journal:  Liver       Date:  1987-02

5.  Telomerase activity in colorectal cancer and its relationship to bcl-2 expression.

Authors:  A Iida; A Yamaguchi; K Hirose
Journal:  J Surg Oncol       Date:  2000-04       Impact factor: 3.454

6.  Telomerase activity and Bcl-2 expression in non-small cell lung cancer.

Authors:  Y Ohmura; M Aoe; A Andou; N Shimizu
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

7.  Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence.

Authors:  K Ohta; T Kanamaru; Y Morita; Y Hayashi; H Ito; M Yamamoto
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

8.  Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases.

Authors:  J Wang; P Lou; J Henkin
Journal:  J Cell Biochem       Date:  2000-04       Impact factor: 4.429

9.  Telomerase activity in hepatocellular carcinoma and adjacent liver tissues.

Authors:  K Kishimoto; J Fujimoto; M Takeuchi; H Yamamoto; T Ueki; E Okamoto
Journal:  J Surg Oncol       Date:  1998-11       Impact factor: 3.454

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

View more
  4 in total

1.  MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.

Authors:  Cheng-Ying Ho; Eli Bar; Caterina Giannini; Luigi Marchionni; Matthias A Karajannis; David Zagzag; David H Gutmann; Charles G Eberhart; Fausto J Rodriguez
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

2.  Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2.

Authors:  Ming Lin; Xuyu Zhang; Bingjie Jia; Su Guan
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

3.  NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells.

Authors:  Ponniah Selvakumar; Ashakumary Lakshmikuttyamma; Umashankar Das; Hari N Pati; Jonathan R Dimmock; Rajendra K Sharma
Journal:  Mol Cancer       Date:  2009-08-24       Impact factor: 27.401

4.  Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.

Authors:  Malgorzata Sztiller-Sikorska; Kamila Koprowska; Kinga Majchrzak; Mariusz Hartman; Malgorzata Czyz
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.